

Title (en)  
AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE

Title (de)  
AMINOPYRIMIDINYL DERIVATIVE ZUR BEHANDLUNG VON PARKINSON'S DISEASE

Title (fr)  
DERIVÉS D'AMINOPYRIMIDINYL POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON

Publication  
**EP 4276097 A1 20231115 (EN)**

Application  
**EP 22386025 A 20220510**

Priority  
EP 22386025 A 20220510

Abstract (en)  
Disclosed are heterobifunctional compounds that can induce the degradation of leucine-rich repeat kinase 2 (LRRK2) and PDE6D. These compounds can engage LRRK2 on one end and bind to an ubiquitin E3 ligase (e.g. cereblon, Von Hippel-Lindau, or Cellular Inhibitor of Apoptosis (cIAP)) on the other end and therefore bring LRRK2 in close proximity to the E3 ligase and induce the ubiquitination and degradation of the LRRK2 protein. Also disclosed are pharmaceutical composition comprising the heterobifunctional compounds and methods of using the compounds to treat LRRK2 and PDE6D-related diseases and disorders.

IPC 8 full level  
**C07D 401/14** (2006.01); **A61P 25/16** (2006.01); **C07K 1/00** (2006.01)

CPC (source: EP)  
**A61P 25/16** (2017.12); **C07D 401/14** (2013.01); **C07K 5/06043** (2013.01); **C07K 5/0606** (2013.01); **C07K 5/06191** (2013.01);  
**A61K 38/00** (2013.01)

Citation (applicant)  

- WO 2020081682 A1 20200423 - DANA FARBER CANCER INST INC [US]
- WO 2021194878 A1 20210930 - ARVINAS OPERATIONS INC [US]
- WO 2021194879 A1 20210930 - ARVINAS OPERATIONS INC [US]
- DORSEY ET AL., J PARKINSONS DIS., vol. 8, no. s1, 2018, pages S3 - S8
- FEIGIN ET AL., LANCET NEUROL., vol. 18, no. 5, May 2019 (2019-05-01), pages 459 - 480
- SHENG ET AL., SCI TRANSL MED, vol. 4, no. 164, 12 December 2012 (2012-12-12), pages 164 - 161
- STEGER ET AL., ELIFE, vol. 5, 2016, pages e12813
- TOLOSA ET AL., NAT. REV. NEUROL., vol. 16, no. 2, 2020, pages 97 - 107
- DENG ET AL., NAT. CHEM. BIOL., vol. 7, no. 4, 2011, pages 203 - 5
- CHOI ET AL., ACS MED CHEM LETT, vol. 3, no. 8, 2012, pages 658 - 662
- FELL ET AL., J. PHARMACOL. EXP. THER., vol. 355, no. 3, 2015, pages 397 - 409
- HENDERSON ET AL., J. MED. CHEM., vol. 58, no. 1, 2015, pages 419 - 32
- DENISTON ET AL., NATURE, vol. 588, no. 7837, 2020, pages 344 - 349
- WATANABE ET AL., CELL, vol. 182, no. 6, 2020, pages 1508 - 1518
- ANDERSEN ET AL., TOXICOLOGY, vol. 395, 2018, pages 15 - 22
- BAPTISTA ET AL., SCI. TRANSL. MED., vol. 12, no. 540, 22 April 2020 (2020-04-22), pages eaav0820
- GAROFALO ET AL., J. MED. CHEM., vol. 63, no. 23, 2020, pages 14821 - 14839
- LESNIAK ET AL., EUR. J. MED. CHEM., vol. 229, 2022, pages 114080
- HELTON ET AL., ACS CHEM. BIOL., vol. 16, no. 11, 2021, pages 2326 - 2338
- TASEGIAN ET AL., BIOCHEM J., vol. 478, no. 19, 2021, pages 3555 - 3573
- KONSTANTINIDOU ET AL., CHEMMEDCHEM, vol. 16, no. 6, 2021, pages 959 - 965
- SCHAPIRA ET AL., NAT. REV. DRUG DISCOV., vol. 18, no. 12, 2019, pages 949 - 963
- DOUGLASS ET AL., J AM CHEM SOC., vol. 135, no. 16, 2013, pages 6092 - 6099
- WIGGIN ET AL., MOL. CELL BIOL., vol. 22, no. 8, April 2002 (2002-04-01), pages 2871 - 81
- LIS ET AL., BIOCHEM J., vol. 475, no. 1, 2 January 2018 (2018-01-02), pages 1 - 22
- BOND, J. MED. CHEM., vol. 64, no. 20, 2021, pages 15477 - 15502
- GIRARDINI ET AL., BIOORG. MED. CHEM., vol. 27, no. 12, 2019, pages 2466 - 2479
- MARTIN ET AL., J. PHYS. CHEM. C, vol. 113, no. 43, 2009, pages 18884 - 18890
- KUCK ET AL., J. CHEM. SOC., PERKIN TRANS., vol. 2, 1990, pages 251 - 256

Citation (search report)  

- [IDA] WO 2020081682 A1 20200423 - DANA FARBER CANCER INST INC [US]
- [AD] WO 2021194879 A1 20210930 - ARVINAS OPERATIONS INC [US]
- [A] PEDRO SOARES ET AL: "Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippel-Lindau (VHL) E3 Ubiquitin Ligase: Structure?Activity Relationships Leading to the Chemical Probe (2 S ,4 R )-1-(( S )-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy- N -(4-(4-methylthiazol", JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, no. 2, 18 September 2017 (2017-09-18), US, pages 599 - 618, XP055531171, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.7b00675

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)  
BA ME

Designated validation state (EPC)  
KH MA MD TN

DOCDB simple family (publication)  
**EP 4276097 A1 20231115**; WO 2023218187 A1 20231116

DOCDB simple family (application)

